Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use ...

Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks ...

Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI: Paris Saturday, October 26, 2024, 12:00 Hrs [IST] Positive data from the ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales(recorded by ...

Patients in this study saw improvements in difficult-to-treat areas when treated with Ebglyss. With Ebglyss, 57% of patients in Week 16 and 60% in Week 24 who had previously been treated with ...

SALES FORECAST: The Paris-based group's sales are forecast at 12.63 billion euros, according to Visible Alpha. That compares with 11.96 billion euros for the same period the year before. As of ...

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved ...

More than 1,000,000 patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been ...